Worldwide more than 200 million individuals are allergic to group 1 grass pollen allergens. We have used the major timothy grass pollen allergen Phl p 1, which cross-reacts with most grass-, corn-, and monocot-derived group 1 allergens to develop a generally applicable strategy for the production of hypoallergenic allergy vaccines. On the basis of the experimentally determined B cell epitopes of Phl p 1, we have synthesized five synthetic peptides. These peptides are derived from the major Phl p 1 IgE epitopes and were between 28-32 amino acids long. We demonstrate by nuclear magnetic resonance that the peptides exhibit no secondary and tertiary structure and accordingly failed to bind IgE antibodies from grass pollen allergic patients. The five peptides, as well as an equimolar mixture thereof, lacked allergenic activity as demonstrated by basophil histamine release and skin test experiments in grass pollen allergic patients. When used as immunogens in mice and rabbits, the peptides induced protective IgG antibodies, which recognized the complete Phl p 1 wild-type allergen and group 1 allergens from other grass species. Moreover, peptide-induced antibodies inhibited the binding of grass pollen allergic patients IgE antibodies to the wild-type allergen. We thus demonstrate that synthetic hypoallergenic peptides derived from B cell epitopes of major allergens represent safe vaccine candidates for the treatment of IgE-mediated allergies.
Potent allergens contain several binding sites for IgE antibodies (i.e., IgE epitopes) and therefore can cause cross-linking of effector cell-bound IgE and the release of biologically active mediators (histamine, leukotriens) (2, 3) . Although the immediate release of biologically active mediators is responsible for most of the acute manifestations of allergy (allergic rhinoconjunctivitis, bronchial asthma, anaphylactic shock), it has been recognized that IgE-mediated presentation of allergens to T cells can induce and perpetuate also chronic symptoms of allergy (atopic dermatitis, chronic bronchial asthma) (4, 5) .
Allergen-specific immunotherapy, the only causative form of allergy treatment, has been introduced in 1911 but is still performed with allergen extracts that are difficult to standardize: mixtures of allergenic and non-allergenic components (6) (7) (8) . Furthermore, systemic administration of allergenic material can induce life-threatening side effects (e.g., anaphylactic shock) in patients. Adsorption of allergen extracts to adjuvants (e.g., aluminum hydroxide) has decreased the systemic spreading of allergens and thus the rate of side effects (9) . The other possibility of reducing side effects by controlled modification of allergens has so far been hampered by the lack of availability of defined allergens (10) . With the application of recombinant DNA technology for allergen characterization it has become possible to produce defined recombinant allergens for diagnosis of Type I allergy and to study the epitopes and structures of important allergens (11) .
Here, we present a generally applicable strategy for the generation of hypoallergenic allergen derivatives for immunotherapy, which is based on the use of IgE-epitope-derived synthetic allergen peptides without allergenic activity for vaccination. Such peptides can be selected from B cell epitopes, which are determined by experimental epitope mapping of major allergens or according to three-dimensional allergen structures (Figure 1 ) (12) .
As a model allergen we have used the major timothy grass pollen allergen, Phl p 1, which represents one of the most important and frequently recognized environmental allergens (13) . Phl p 1 belongs to the family of group 1 grass pollen allergens that are present in most grasses, corn, and monocots as highly cross-reactive allergens (14) (15) (16) . We have isolated the cDNA coding for Phl p 1 and produced a recombinant Phl p 1 molecule, which reacted with serum IgE from 95% of grass pollen allergic patients (13) . Recombinant Phl p 1 cross-reacted with group 1 allergens from eight monocots and elicited immediate-type skin reactions in grass pollen allergic patients (13, 17) . Recently, we determined by gene fragmentation the IgE and IgG epitopes of Phl p 1 (18) . Using the results from the epitope mapping studies, we have now prepared five synthetic peptides, which are derived from the Phl p 1 epitopes, each of a length between 28-32 amino acids. The peptides were analyzed for secondary and tertiary structure by nuclear magnetic resonance (NMR) and tested for IgE reactivity. The lack of allergenic activity of the five peptides was demonstrated by basophil histamine release and skin-prick testing. Furthermore we studied whether immunization of mice and rabbits with the peptides induces IgG antibody responses against the Phl p 1 wild-type allergen and against group 1 allergens from other grass species. Finally, we studied the protective nature of the peptide-induced antibodies by analyzing their capacity to inhibit the binding of grass pollen allergic patients IgE antibodies to the complete Phl p 1 wild-type allergen. The surprising finding that IgG antibodies against one particular non-allergenic peptide inhibited up to 90% of patients IgE binding to complete Phl p 1 is discussed regarding the use of this peptide for vaccination against grass pollen allergy.
Furthermore we suggest the B cell epitope-derived peptide vaccine approach as general strategy for specific treatment of IgE-mediated allergies.
MATERIALS AND METHODS

Natural allergen extracts, recombinant allergens
Pollen from different grasses (Phleum pratense, Lolium perenne, Poa pratensis, Dactylis glomerata) and corn (Secale cereale), were purchased from Allergon Pharmacia (Välinge, Sweden). Aqueous pollen extracts were prepared and checked for quantity and quality of proteins by SDS-PAGE and Coomassie blue staining as described (19) (20) (21) . Purified recombinant Phl p 1, which had been expressed in E. coli, was obtained from BIOMAY (Vienna, Austria).
Synthesis, purification, and characterization of peptides
Five peptides (between 28 to 32 amino acids) from the five major IgE epitope-containing regions of Phl p 1 were selected ( Table 1 ). The IgE epitope-containing regions were isolated from an epitope library constructed from randomly digested Phl p 1-encoding cDNA. ß-galactosidasefused recombinant peptides were identified with serum IgE antibodies of grass pollen allergic patients (18, 22) . Peptide sequences with a length of >25 amino acids were selected to obtain immunogenic peptides. Phl p 1 areas were chosen, which were identified by several independently obtained IgE-reactive epitope clones. The length of the peptides was dictated by technical considerations regarding synthesis chemistry and the consideration that peptides longer than 35 amino acids may become IgE-reactive or allergenic.
Peptides were synthesized by using a Fmoc (9 fluorenyl methoxy carbonyl)-strategy with HBTU [(2-(1H-Benzotriazol-1-yl)1,1,3,3 tetramethyluronium hexafluorophosphat] activation (0.1 mmol small-scale cycles) on the Applied Biosystems (Foster City, CA) peptide synthesizer Model 433A. Preloaded PEG-PS (polyethylenglycol polysterene) resins (0.15-0.2 mmol/g loading; Per Septive Biosystems, Warrington, UK) were used as solid phase to build up the peptides. Chemicals were purchased from PE Applied Biosystems. Coupling of amino acids was confirmed by conductivity monitoring with feedback control. One cysteine residue was added to the C-termini of peptides 1-3 and to the N-terminus of peptide 5 to facilitate coupling of the peptides to carriers. Peptide 4 contained a natural cysteine residue at the C-terminus. Peptides were cleaved from the resins with the following mixture: 250 µl distilled water, 250 µl triisopropylsilan (Fluka, Buchs, Switzerland), and 9.5 ml trifluoraceticacid for 2 h and precipitated in tert-butyl methyl ether (Fluka, Buchs, Switzerland). The identity to the peptides was checked by mass spectrometry, and the peptides were purified to >90% purity by preparative HPLC (piChem, Graz, Austria).
NMR analysis of peptides
Peptides were examined for tertiary and/or secondary structure by one-and two-dimensional NMR performed on a Unity Varian 500 MHz spectrometer equipped with z-shielded gradient coils. Samples were analyzed at a concentration between 0. 
Characterization of allergic patients
Grass pollen allergic patients suffering from allergic rhinoconjunctivitis and/or asthma to grass pollen were selected according to case history indicative for seasonal grass pollinosis (23) . The diagnosis of grass pollen allergy was confirmed by skin-prick testing with grass pollen extract (ALK, Horsholm, Denmark) and serological CAP RAST (Pharmacia Diagnostics, Uppsala, Sweden) testing. Total IgE levels in the sera were determined by CAP RIST measurements (Pharmacia). IgE antibodies specific for rPhl p 1 were determined by ELISA (Table 2 ) (23).
Sera from 60 grass pollen allergic patients were analyzed in total. Sera from 46 representative patients ( 24 men, 22 women, mean age 30 years (range 19-62 years) and from one non-atopic person were used for IgE binding and IgE inhibition studies ( Table 2) .
Immunization of mice and rabbits
HPLC-purified peptides were coupled to KLH (Keyhole limpet hemocyanin, Pierce, Rockford, IL, MW 4.5 × 10 3 -1.3 × 10 7 ) using an Imject Maleimide Activated Immunogen Conjugation Kit (Pierce), according to the manufacturers instruction. KLH-conjugated peptides or complete recombinant Phl p 1 were used to immunize rabbits using CFA as adjuvant (Charles River, Kißlegg, Germany).
In addition, six-week-old female BALB/c mice were purchased from Charles River and immunized with the peptides. Animals were maintained in the animal care unit of the Institute of Pathophysiology, University of Vienna, according to the local guidelines for animal care. Groups of six mice were treated with each peptide: From each group, two mice were immunized subcutaneously in approximately four-week intervals with each of the uncoupled peptides (50 µg) adsorbed to CFA, two mice received KLH-coupled peptide (100 µg) adsorbed either to Al(OH) 3 (Alu-Gel-S, Serva, Ingelheim, Germany) or CFA (Sigma-Aldrich, Vienna, Austria). Mice were bled from the tail veins and sera were stored at -20Û&XQWLODQDO\VLV Immune responses were examined by ELISA (24) . In short Nunc Maxisorp plates (Roskilde, Denmark) coated with rPhl p 1 (5µg/ml) were incubated with mouse-sera (1:500) and bound antibodies were detected with a monoclonal rat anti-mouse IgG 1 (Pharmingen, San Diego, CA, USA, 1:1000) and a HRP-labeled sheep anti-rat antiserum (Amersham, Buckinghamshire, UK, 1:2000). Rabbit anti-peptide antibodies (serum dilutions 1:1000, 1:5000, 1:10000) were detected with a 1:2000 diluted HRP-labeled donkey anti-rabbit antiserum (Amersham).
Basophil histamine-release
Granulocytes were isolated from heparinized blood samples of grass pollen allergic individuals by dextran sedimentation (25) . Cells were incubated with increasing concentrations (10 -8 to 10 µg/ml) of each peptide and for control purposes with complete rPhl p 1 and monoclonal antihuman IgE antibodies. In addition histamine release experiments were performed with peptides and rPhl p 1 (each protein or peptide at a concentration of 0.1 µg/ml), which were coupled to aluminum hydroxide (3.3 µg) or KLH (0.1-0.2 µg). For control purposes, basophils were exposed to aluminum hydroxide or KLH alone. Histamine released in cell-free culture supernatants was measured by radioimmunoassay (Immunotech, Marseille, France). Total histamine was determined after freezing and thawing of cells. Results are displayed as mean values of triplicate determinations.
Skin-prick testing (SPT) of allergic patients
The in vivo allergenic activity of the peptides was studied by skin-prick testing in eight grass pollen allergic patients and two non-atopic controls by using 20 µl aliquots containing 100 µg/ml of each peptide or a mixture containing 20 µg/ml of each peptide (17) . In addition, rPhl p 1 (5 different concentrations: 5, 10, 25, 50, and 100 µg/ml), timothy grass pollen extract, histamine and sodium chloride (ALK, Horsholm, Denmark) were tested. Reactions were recorded 20 min after testing by photography and by transferring the ballpoint pen-surrounded wheal area with a scotch tape to paper. The mean wheal diameter (Dm) was calculated by measuring the maximal longitudinal and transversal diameters in millimeters and dividing the sum by 2.
ELISA detection of peptide and rPhl p 1-specific antibodies and inhibition of IgE binding of allergic patients' IgE to Phl p 1 by peptide-induced IgG
Detection of allergic patients' IgE antibodies to rPhl p 1 and rPhl p 1-derived peptides was performed by ELISA (23) . ELISA plates (Nunc) were coated with rPhl p 1-derived isolated or KLH-coupled peptides (5 µg/ml) and rPhl p 1 as control (5 µg/ml), then washed and blocked. Subsequently, plates were incubated with 1:3 diluted sera from 46 grass pollen allergic patients and from a non-atopic person. Bound IgE was detected with alkaline-phosphatase-coupled (AP) mouse monoclonal anti-human IgE antibody (1:1000, Pharmingen, San Diego, CA).
The ability of peptide-induced rabbit Ig to inhibit the binding of allergic patients' IgE antibodies to complete rPhl p 1 was examined by ELISA competition assay as described (26) . rPhl p 1-coated (1µg/ml) plates (Nunc) were preincubated with 1:250-diluted rabbit anti-peptide antisera, a rabbit anti-rPhl p 1 antiserum and, for control purposes, with the corresponding preimmune sera. After washing, plates were incubated with human sera (1:3 diluted) from grass pollen allergic patients and bound IgE was detected with mouse anti-human IgE-AP (Pharmingen, 1:1000). The percentage of inhibition of IgE binding achieved by preincubation with the antipeptide antisera was calculated as follows: % inhibition of IgE binding = 100 -OD I /OD P × 100. OD I and OD P represent the extinctions after preincubation with the rabbit immune and preimmune serum, respectively.
Cross-reactivity of anti-peptide antisera as determined by immunoblotting
Reactivity of peptide-induced IgG antibodies to natural Phl p 1 and homologous allergens in three different grass pollen (Lolium perenne, Poa pratensis, Dactylis glomerata) and one corn pollen (Secale cereale) was studied by immunoblotting. Allergen extracts were separated by 12% preparative SDS-PAGE (15 µg protein/cm gel) and blotted onto nitrocellulose membranes (Schleicher & Schüll, Dassel, Germany) (27) . Nitrocellulose strips were exposed to mouse sera (diluted 1:1000). Bound mouse IgG 1 antibodies were detected with monoclonal rat anti-mouse IgG 1 antibody (Pharmingen) and a 125 I-labeled sheep anti-rat antiserum (Amersham, 1:2000) (24) .
RESULTS
Selection and characterization of five synthetic peptides derived from the Phl p 1 IgE-epitopes
Five peptides representing portions of the major IgE epitope-bearing domains of Phl p 1 were synthesized (18) ( Table 1 ). An additional cysteine was added to the C-, and N-terminus, of peptides 1-3 and 5, respectively. Peptide 4 contained a natural cysteine at its C-terminus. Cysteines were required for coupling the peptides to KLH to perform immunization experiments. Only one of the five peptides (peptide 2) contained a T cell epitope recognized by allergic patients (28) . The molecular weights of the peptides ranged from 2920.3 to 3482.9 Dalton and the isoelectric points of the peptides were in the range from 4.07 (P2) to 9.41 (P4) ( Table 1) .
Peptides were checked for tertiary and/or secondary structure by NMR (Fig. 2 , Table 1 ). The presence of residual tertiary and/or secondary structure of the synthetic peptides was probed by one-and two-dimensional (1 and 2D) NMR. This technique has the advantage compared with other spectroscopical approaches in that it provides positional information along the sequence. As exemplified for peptides 2, 3, and 4, one-dimensional NMR experiments clearly showed absence of tertiary structure in all five peptides: All the resonances have poor spectral dispersion as expected for mixtures of amino acids or peptides without tertiary fold (Fig. 2A) . The absence of ring current shifted peaks in the region of the spectra below 0.5 parts per million is also a common characteristic of the spectra of all the five peptides ( Fig. 2A) . Ring current shifts are typical features of folded proteins in which aliphatic chains get in persistent proximity to aromatic rings, which induce a magnetic current in addition to the external magnetic field. Their absence is therefore an additional indication of lack of tertiary fold.
To look for the presence of residual secondary structure, two-dimensional experiments were performed that would provide spectral assignment and information about spatial arrangement of the peptides. For all peptides except P3, the only observed distances arising from NOESY experiments, which directly indicate a spatial proximity below 5A between protons, were the intraresidual ones. No sequential HN-HN or long distance HA-HA NOESY connectivities were observed, which could suggest the presence of some helical or beta-stranded structure. This finding indicates absence of secondary structure. The NOESY spectrum of peptide 3 is the only one that contains HN-HN and HB-HN connectivities that, once assigned, correlate residues between T11 and K28 (Fig. 2B) . These effects are typical of a "nascent helix", which is a conformation that tends to be helical even though it is not stabilized adequately . Such a conformation is characteristic of isolated peptides with strong helical propensity.
Phl p 1-derived peptides lack IgE binding capacity and allergenic activity
The isolated as well as KLH-coupled Phl p 1-derived peptides were compared with complete rPhl p 1 regarding IgE-binding capacity by ELISA (Table 2 ). The results of 46 representative patients are summarized in Table 2 . Total IgE levels and timothy grass pollen-specific IgE levels ranged from 30.3 to 2000 kU/L (mean: 354 kU/L) and 9.1-100 kUA/L (mean: 48 kUA/L), respectively. All 46 patients contained rPhl p 1-specific IgE antibodies ranging between 0.1-2.160 OD units (mean: 0.664) but no serum contained detectable IgE antibodies with specificity for any of the five isolated (P1-P5) or KLH-coupled (KLH-P1-KLH-P5) peptides (Table 2) . Comparable results were obtained with sera from additional 14 grass pollen allergic patients. The coupling of the peptides as well as of rPhl p 1 to the ELISA plates was confirmed with peptidespecific rabbit antisera (data not shown).
The in vitro allergenic activity of the Phl p 1-derived peptides was compared with complete rPhl p 1 by basophil histamine release tests by using granulocytes from grass pollen allergic individuals containing Phl p 1-specific IgE antibodies. As exemplified in the experiment shown in Fig. 3A , none of the five peptides elicited histamine release up to concentrations of 10 µg/ml, whereas complete rPhl p 1 induced a dose-dependent histamine release starting between 10 -3 to 10 -4 µg/ml with a maximal release at 0.1 µg/ml. Anti-IgE antibodies also induced a dosedependent histamine release from the patient's basophils (Fig. 3A) . On the basis of the histamine release tests obtained in this and other experiments (data not shown), we estimated that Phl p 1-derived peptides have at least a 10,000-to 100,000-fold reduced allergenic activity compared with rPhl p 1. The reduction of allergenic activity may however be even higher because the peptides did not induce allergic reactions in the highest concentrations that were applied.
To investigate whether coupling of the peptides to KLH or aluminum hydroxide would yield allergenic peptide conjugates/adsorbates, additional histamine release experiments were performed in two Phl p 1 allergic patients (Fig. 3B, 3C) . Results obtained showed that neither the coupling to KLH nor the adsorption to aluminum hydroxide yielded highly allergenic peptide derivates. Only the peptide 4-KLH conjugate induced mild histamine release in one patient (Fig.  3B) , whereas the other derivates failed to induce significant histamine release over the background level (i.e., histamine release induced by KLH and aluminum hydroxide alone). rPhl p 1 and rPhl p 1 coupled to KLH and aluminum hydroxide as well as anti-IgE antibodies induced histamine release in both patients.
The in vitro test results were confirmed by skin-prick test experiments performed in eight grass pollen allergic patients and two non-atopic controls (Fig. 4, Table 3 ). None of the eight grass pollen allergic patients reacted with any of the peptides or the peptide mixture even when they were tested at a concentration of 100 µg/ml for the individual peptides or as mix containing 20 µg/ml of each of the five peptides. In contrast, complete rPhl p 1 induced immediate-type skin reactions in seven patients already at a concentration of 5 µg/ml and in one patient at a concentration of 10 µg/ml. All grass pollen allergic patients also displayed immediate skin reactions to timothy grass pollen extract. All individuals reacted with histamine. The non-atopic persons showed no reactions to timothy grass pollen extract, rPhl p 1 and rPhl p 1-derived peptides (Table 3) . No late reactions were found in any of the tested persons when we checked the application sites 24-48 h after skin-prick testing (data not shown).
Immunization with Phl p 1-derived peptides induces IgG antibody responses to complete Phl p 1 and homologous group 1 allergens from other grass species
To evaluate whether immunization with Phl p 1-derived peptides will induce IgG antibodies that react with complete Phl p 1 and homologous allergens, mice and rabbits were immunized with peptides and KLH-conjugated peptides using two different adjuvants, CFA, and Al(OH) 3 (Alu). As can be seen in the time courses of the immunizations, all five peptides induced IgG 1 anti-rPhl p 1 antibody responses, which could be detected 4-8 weeks after the first immunization and which increased after the first two immunizations (Table 4) . Alu-adsorbed KLH-coupled peptides gave lower mouse IgG 1 titers than KLH-coupled CFA-adsorbed peptides but were of similar magnitude as the IgG 1 responses induced with CFA-adsorbed unconjugated peptides ( Table 4 ). The peptide-induced IgG 1 anti-rPhl p 1 responses increased during the immunizations.
Similar results were obtained after immunization of rabbits with KLH-conjugated peptides, which were administered subcutaneously with CFA. All five peptides induced IgG anti-rPhl p 1 antibody responses, which increased during the course of immunization. Comparing the results of the different mouse immunizations, peptides 2-5 induced higher levels of Phl p 1-specific antibody responses than peptide 1 and thus seemed to be more immunogenic than peptide 1 (Table 4) . Similar results were obtained when rabbits were immunized. Figure 5 shows the titration of rabbit antisera raised against P1-P5 and against complete rPhl p 1. The rabbit anti-P1, anti-P2, and anti-P3 antisera showed weaker reactivity to rPhl p 1 than the antiserum raised against complete rPhl p 1. However, the titration experiment indicated that the titers of the peptide antisera and the anti-rPhl p 1 antiserum did not differ for more than a factor of 10 ( Fig.  5) . In rabbits, peptide 5 appeared to be the most immunogenic peptide.
Next we were interested in whether anti-Phl p 1 peptide antisera cross-react with Phl p 1-related allergens from three grasses (Lolium perenne, Poa pratensis, Dactylis glomerata) and a corn (Secale cereale). Almost all mouse anti-peptide antisera exhibited broad cross-reactivity with group 1 allergens from the various grass and corn species (Fig. 6) . Few anti-peptide antisera (e.g., anti-peptide antisera 1 and 2 in the Alu group and anti-peptide antiserum 4 in the CFA group) exhibited weak cross-reactivity. Comparing the intensity of reactivity of these antisera with natural Phl p 1, it seemed that the weak cross-reactivity of these antisera was rather due to low antibody titers than to limited cross-reactivity. This assumption was also supported by the comparison of the Phl p 1-derived peptide sequences with those of other group 1 allergens showing a high degree of sequence conservation (data not shown).
Anti-peptide antisera inhibit the binding of grass pollen allergic patients' IgE to complete Phl p 1
The capacity of anti-Phl p 1 peptide antibodies to inhibit the binding of allergic patients' IgE to complete rPhl p 1 was examined by ELISA competition experiments using sera from 52 grass allergic patients. In the majority of patients (n=46), we observed strong inhibition of IgE binding (Table 5 ). In six patients the anti-peptide antisera failed to inhibit IgE binding to rPhl p 1 (data not shown).
Rabbit anti-peptide 5 antibodies inhibited IgE binding to complete rPhl p 1 in all 46 patients (10%-87% inhibition; average: 53.8%). Anti-peptide 1-4 antisera gave a much lower inhibition of IgE binding (mean inhibitions: anti-P1: 5.5%; anti-P2: 9.2%; anti-P3: 19.2%; anti-P4: 15.3%). These antisera inhibited IgE binding much less than the anti-peptide 5 antiserum. The inhibition achieved with a mixture of all five antisera was not stronger than that obtained with the antipeptide 5 antiserum alone (average inhibition with anti-P5: 53.8%; average inhibition with anti-P1-P5: 45.8%) ( Table 5 ). The possibility that mixing of the different antisera might have caused a steric inhibition between the anti-peptide antibodies seemed unlikely because the addition of single anti-peptide antisera to anti-P5 antibodies did not significantly alter the results achieved with the anti-P5 antiserum alone (data not shown).
What we found even more interesting was that rabbit antibodies raised against complete rPhl p 1 inhibited IgE binding to rPhl p 1 to a lower degree (average inhibition 38.2%) than anti-P5 antibodies or the mix of anti-P1-P5 antibodies (Table 5) . No association between the levels of rPhl p 1-specific IgE in the sera and the degree of inhibition by the anti-peptide antisera was observed (Tables 2, 5 ).
DISCUSSION
In this study, we show that vaccination with non-anaphylactic peptides derived from B cell epitopes may be a generally applicable strategy for the therapy of Type I allergies. We demonstrate that synthetic peptides derived from the IgE epitopes of one of the most important environmental allergens, the major timothy grass pollen allergen, Phl p 1, lack allergenic activity but induce protective antibody responses. Similar results were obtained with surface-exposed peptides of the major birch pollen allergen, Bet v 1, supporting our assumption that the presented approach has general applicability (29) .
The approach of using B cell epitope-derived hypoallergenic peptides for allergy vaccination is different from the strategy of using T cell epitope-derived peptides for allergy treatment, because T cell peptides exert their effects preferentially via the induction of tolerance or anergy in allergen-specific T cells (30) (31) (32) .
The possibility of obtaining hypoallergenic peptides by proteolytic digestion of allergen extracts for immunotherapy of allergic diseases has been indicated by classical experiments performed more than 30 years ago (33, 34) . However, difficulties to prepare standardized peptide mixtures from crude allergen extracts may have hampered a broader use of this technology. Recombinant DNA technology has now made it possible to produce defined allergen components as recombinant proteins that equal their natural counterparts and has facilitated the mapping of allergen epitopes (11, 12) . The importance of individual allergen components can now be evaluated in vitro and in vivo and IgE epitopes can be determined by controlled allergen fragmentation and/or structural biology methods (12) .
According to the experimentally determined IgE epitopes of the major timothy grass pollen allergen, Phl p 1, we have synthesized five epitope-derived peptides (18) . In contrast to the IgEreactive ß-galactosidase-fused peptides previously described, the synthetic peptides did not bind IgE antibodies and failed to elicit allergic reactions in vitro and in vivo up to concentrations of 100 µg/ml. In agreement with the lack of allergenic activity, NMR analysis of the peptides showed that none of the peptides exhibited signs of stable secondary or tertiary structure. The lack of IgE binding capacity and allergenic activity may therefore be due to the low likelihood that IgE epitopes capable of cross-linking effector cells are present on the isolated fragments and due to the destruction of conformational IgE epitopes.
Despite their lack of IgE reactivity, all five peptides induced in vivo IgG antibodies, which reacted with the complete wild-type Phl p 1 allergen and cross-reacted with group 1 allergens from other grass and corn species. This finding indicates that the peptides contained sufficient sequence motifs for the induction of antibodies, which are capable of recognizing complete group 1 allergens. Synthetic peptides derived from the Phl p 1 allergen may thus be used not only to treat timothy grass pollen allergy but also allergies to other grass and corn species. The latter assumption is supported by the demonstration that Phl p 1 contained many of the relevant epitopes present in group 1 allergens from other monocots and by our finding that peptideinduced antibodies cross-reacted with group 1 allergens from a variety of monocots (13, 16, 28) .
More important is the finding that the peptide-induced antibodies could inhibit the binding of grass pollen allergic patients' IgE to the complete Phl p 1 wild-type allergen. The most potent inhibition of IgE binding (up to 87%, average 53.8%) was achieved with antibodies induced against one particular peptide, (peptide 5), whereas antibodies directed against other IgE binding sites were less potent inhibitors of IgE recognition. The latter result may be explained by the fact that Phl p 1-specific antibody levels in the anti-P1-P4 antisera were lower than in the anti-P5 antiserum. Because a mixture of antibodies against all five peptides did not yield stronger inhibition of IgE binding than the anti-P5 antibodies, the peptide P5 may be sufficient for the treatment of a high percentage of patients allergic to group 1 grass pollen allergens. This assumption is supported by our finding that the anti-P5 antiserum inhibited IgE binding to Phl p 1 equally well as an antiserum raised against the complete recombinant Phl p 1 allergen.
Although we could not achieve inhibition of IgE binding in all of the tested patients with the peptide-induced antibodies, we think that the approach of using B cell epitope-derived peptides has many advantages. First, it is possible to produce well-characterized hypoallergenic and thus safe vaccines for allergy treatment. Second, the peptides can be used to focus blocking antibodies directly to or close to the major IgE binding sites of important allergens. The importance of focusing blocking antibodies to the IgE-reactive portions of allergens is supported by other studies showing that IgG antibodies induced by immunotherapy may also recognize epitopes other than those recognized by IgE and thus may fail to inhibit IgE binding or even enhance the IgE recognition of allergens (26, 35) .
From classical experiments performed more than 60 years ago we know that blocking antibodies induced in allergic patients and in non-atopic persons can suppress the IgE mediated activation of effector cells and thus the immediate symptoms of Type I allergy (36) (37) (38) . More recently it has been even demonstrated that immunotherapy-induced blocking antibodies can also inhibit the IgE-mediated presentation of allergens to T cells and thus the chronic manifestations of atopy (39) .
On the basis of ours and the other data, we expect that blocking antibodies induced by vaccination with Phl p 1 peptides will have several beneficial effects. Peptide-induced antibodies will reduce Phl p 1-induced effector cell activation, prevent production of Phl p 1-specific IgE synthesis, and inhibit IgE-mediated T cell activation. However, the hypoallergenic Phl p 1-derived peptides described now need to be evaluated in controlled immunotherapy studies for the therapy of grass pollen allergy. Should the clinical immunotherapy studies confirm the in vitro results, the principle of using B cell epitope-derived peptides may be applied as a general strategy to produce safe allergy vaccines for all allergens of which the IgE epitopes or threedimensional structures are known. 
